DOJOLVI

Peak

triheptanoin

NDAORALLIQUID
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

medium-chain triglyceride consisting of three odd-chain 7-carbon length fatty acids (heptanoate) that provide a source of calories and fatty acids to bypass the long-chain FAOD enzyme deficiencies for energy production and replacement.

Pharmacologic Class:

Medium-chain Triglyceride

Clinical Trials (5)

NCT07097311Phase 2Recruiting

Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Started Jul 2026
24 enrolled
Medium-chain Acyl-CoA Dehydrogenase Deficiency
NCT06067802Phase 2Suspended

Study of Triheptanoin for the Prevention of Hypoglycemia in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Started Feb 2026
8 enrolled
Medium-chain Acyl-CoA Dehydrogenase Deficiency
NCT06340685Phase 1Recruiting

Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency

Started Jul 2024
6 enrolled
Pyruvate Dehydrogenase Complex Deficiency
NCT05933200Phase 3Active Not Recruiting

A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD

Started Feb 2023
69 enrolled
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
NCT03665636Phase 1Completed

Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I

Started Oct 2020
4 enrolled
Glycogen Storage Disease Type I

Loss of Exclusivity

LOE Date
Nov 14, 2034
105 months away
Patent Expiry
Nov 14, 2034
Exclusivity Expiry
Jun 30, 2027

Patent Records (2)

Patent #ExpiryTypeUse Code
8697748
Apr 28, 2029
Product
12551461
Nov 14, 2034
Product